###begin article-title 0
###xml 96 101 <span type="species:ncbi:9606">women</span>
###xml 135 140 <span type="species:ncbi:9606">women</span>
The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 69 89 <span type="species:ncbi:10566">human papillomavirus</span>
###xml 91 94 <span type="species:ncbi:10566">HPV</span>
###xml 131 134 <span type="species:ncbi:10566">HPV</span>
###xml 374 377 <span type="species:ncbi:10566">HPV</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
###xml 708 713 <span type="species:ncbi:9606">women</span>
###xml 755 760 <span type="species:ncbi:9606">women</span>
Cervical cancer is due to infection with specific high-risk types of human papillomavirus (HPV). Although the incidence of genital HPV infection in various population groups is high, most of these regress without intervention. Investigating genetic host factors and cellular immune responses, particularly cytokines, could help to understand the association between genital HPV infection and carcinogenesis. The tumor necrosis factor alpha (TNF-alpha) cytokine plays an important role in all stages of cervical cancer and has the ability to induce the regression of human tumors. Therefore the aim of the study was to investigate the allelic distribution of -308 TNF-alpha gene polymorphism in South African women with cervical cancer compared to control women.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 27 32 <span type="species:ncbi:9606">women</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
Included in our study were women with histologically proven cancer of the cervix (n = 244) and hospital-based controls (n = 228). All patients and controls were from mixed race and black population groups in South Africa. The detection of a bi-allelic -308 (A/G) polymorphism in the promoter region of TNF-alpha was investigated using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique. The distributions of the allelic frequencies were stratified in both patients and controls into two South African ethnic population groups.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 204 206 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
In this study we observed no association between the distribution of -308 TNF-alpha polymorphism and the risk of developing cervical cancer even after combining the data from the two ethnic populations (X2 = 2.26). In addition, using the chi-squared test we found no significant association between the known risk factors for cervical cancer and the allele distribution of -308 TNF-alpha. However, the frequency of the rare high-producing allele -308A of TNF-alpha was significantly lower in the South African population when compared to Caucasians and Chinese population groups.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
We demonstrated no association between -308 TNF-alpha polymorphism and the risk of cervical cancer among two South African ethnic population groups. However, as the distribution of the -308A TNF-alpha was notably different between the control groups of South Africa and other population groups this result suggests that ethnic disparity may influence the levels of TNF-alpha produced.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 576 577 576 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 842 843 842 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 113 133 <span type="species:ncbi:10566">human papillomavirus</span>
###xml 138 141 <span type="species:ncbi:10566">HPV</span>
###xml 242 247 <span type="species:ncbi:9606">women</span>
###xml 300 303 <span type="species:ncbi:10566">HPV</span>
###xml 422 425 <span type="species:ncbi:10566">HPV</span>
###xml 487 490 <span type="species:ncbi:10566">HPV</span>
###xml 691 694 <span type="species:ncbi:10566">HPV</span>
###xml 797 800 <span type="species:ncbi:10566">HPV</span>
###xml 816 819 <span type="species:ncbi:10566">HPV</span>
There is strong epidemiological and experimental data that have demonstrated a definite association of high-risk human papillomavirus (HR-HPV) infection and the development of cervical cancer [1]. Interestingly, although most sexually active women in the normal population have asymptomatic cervical HPV infections, most of these cervical infections are transient, with clearance in 70% to 90% of individuals positive for HPV DNA. In addition, only a small percentage develops long-term HPV infection, which is associated with an increased risk of developing cervical cancer [2]. Thus, an effective host immune response may be an important determinant for the persistence and progression of HPV induced cervical cancer. In particular, cell-mediated immunity (CMI) is important in controlling both HPV infections and HPV-associated neoplasms [3]. CMI is regulated by cytokines that are secreted primarily by T helper (Th) cells and macrophages.
###end p 11
###begin p 12
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 978 979 978 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 980 981 980 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1282 1284 1278 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 57 60 <span type="species:ncbi:10566">HPV</span>
###xml 269 272 <span type="species:ncbi:10566">HPV</span>
###xml 534 537 <span type="species:ncbi:10566">HPV</span>
###xml 690 695 <span type="species:ncbi:9606">women</span>
Cytokines play a significant role in the defense against HPV induced infections, modulating viral replication and polarizing the immune response to a Th1 (cellular) or Th2 (humoral) pattern [1]. Th1 cells are immuno-stimulatory and are associated with the clearance of HPV infection and regression of cervical intraepithelial neoplasia [4] Th2 cells are immuno-inhibitory and are capable of stimulating tumor growth [5]. Investigating genetic host factors and immune responses could help to understand the association between genital HPV infection and carcinogenesis [6], as cervical cancer is the second most common female cancer worldwide and the most common cancer in South Africa among women, which continues to be a public health burden. Several candidate gene studies have demonstrated that genetic polymorphisms in cytokine genes contribute to the variation in the levels of cytokine produced and this variation may influence the severity of several infectious diseases [7-9]. Among them the pro-inflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha) has been of particular interest as it was found to be located in the central major histocompatibility complex (MHC) and a possible genetic correlation between TNF alleles and disease susceptibility was hypothesized [10].
###end p 12
###begin p 13
###xml 170 172 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 310 312 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 417 419 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 543 545 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 546 548 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 549 551 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 705 706 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 707 709 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 710 712 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 741 743 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 744 746 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1188 1190 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1191 1193 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1532 1533 1492 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1534 1536 1494 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1537 1539 1497 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1540 1542 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
TNF-alpha is a multifunctional cytokine that was originally identified as a macrophage-derived serum protein that mediates necrosis of solid tumors in vitro and in vivo [11]. In addition, TNF has been shown to mediate carcinogenesis through induction of proliferation, invasion, and metastasis of tumor cells [12]. Furthermore, it was shown that the expression of TNF-alpha is regulated at the transcriptional level [13] and various polymorphisms within the TNF-alpha promoter region have been associated with the level of TNF-alpha produced [10,14,15]. Several investigators have studied the polymorphisms within the TNF-alpha promoter region to estimate the immune responses to a wide range of cancers [9,16,17] including cervical cancer [18,19]. In particular, the biallelic polymorphism in the promoter region at position -308 relative to the transcriptional start site of the gene, representing a transition from the nucleotides guanine (G) to adenine (A) has been commonly studied. This -308G/A transition affects the expression of TNF-alpha where the less common -308A allele produces higher levels of TNF-alpha, while the -308G allele is linked to a reduced TNF-alpha production [10,20]. Indeed, these observations presented the possibility that tumor development may be associated to the genetic predisposition of the host to produce higher levels of TNF-alpha. Numerous studies have investigated the association between the effect of TNF-alpha promoter region and cervical cancer, but the results have been contradictory [9,18,21,22]. Notably, these findings are from different population groups and thus indicate that the variation in TNF-alpha production may be influenced by the genetic make-up of diverse population groups contributing to a disparity in disease outcome.
###end p 13
###begin p 14
Therefore, given the importance of TNF-alpha in potentially contributing to the progression of cervical cancer with variations in the levels of TNF production in different population groups, we investigated the biallelic polymorphism in the -308 promoter region of the TNF-alpha gene using the ARMS-PCR methodology and examined its relationship to the development of cervical cancer among two South African ethnic groups.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and control populations
###end title 16
###begin p 17
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 158 163 <span type="species:ncbi:9606">women</span>
###xml 402 407 <span type="species:ncbi:9606">women</span>
###xml 545 550 <span type="species:ncbi:9606">women</span>
###xml 1056 1061 <span type="species:ncbi:9606">women</span>
###xml 1129 1137 <span type="species:ncbi:9606">patients</span>
Individuals were selected from a case-control study of cancer of the cervix and related risk factors conducted among colored (mixed racial descent) and black women residing in the Western Cape Province of South Africa, from January 1998 to December 2001 [23]. The Research Ethics Committee, Faculty of Health Sciences, University of Cape Town, South Africa, approved the case-control study. Cases were women with invasive cancer of the cervix attending Gynae-oncology clinics at 2 tertiary hospitals. The controls, who were hospital based, were women with primary diagnosis such as trauma or acute infections that were judged to be independent of contraceptive use and had no history or evidence of cervical disease and were identified at the 2 tertiary hospitals. The controls were series matched to cases for decade age, ethnic group and area of residence. Data on known risk factors and potential confounders were collected using a detailed questionnaire administered by trained nurse interviewers. Papanicoloau (Pap) smears were taken from all control women. Blood samples from randomly selected 244 eligible cervical cancer patients and 228 hospital-based controls were analysed for the -308 polymorphisms in the promoter region of TNF-alpha.
###end p 17
###begin title 18
DNA extraction
###end title 18
###begin p 19
Genomic DNA was extracted from 200 mul of whole blood using the QiAamp Spin Blood Kit (QIAGEN, Valencia, CA) in accordance with manufacturer's instructions.
###end p 19
###begin title 20
Cytokine genotyping
###end title 20
###begin p 21
###xml 223 225 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
The A and G alleles at position -308 in the promoter region of the TNF-alpha gene were identified using the amplification refractory mutation system polymerase chain reaction (ARMS-PCR) methodology as previously described [24]. A total of 2 ul (25-100 ng) of DNA was used in each ARMS-PCR reaction. The PCR primer sequences were as follows:
###end p 21
###begin p 22
Generic primer (antisense): 5'-tctcggtttcttctccatcg-3'
###end p 22
###begin p 23
Primer G, allele1 (sense): 5'-ataggttttgaggggcatgg-3'
###end p 23
###begin p 24
Primer A, allele2 (sense): 5'-aataggttttgaggggcatga-3'
###end p 24
###begin p 25
The amplified ARMS-PCR products (PCR product size = 184 bp) were identified by gel electrophoresis on 2 % agarose gels stained with ethidium bromide.
###end p 25
###begin title 26
Statistical analysis
###end title 26
###begin p 27
###xml 178 179 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 179 181 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
Statistical analyses were performed using STATA version 8. The allele frequency of the -308 TNF-alpha polymorphism was compared between the patients and control groups using the X2 test. Unconditional logistic regression was used to estimate odds ratios (OR's) for developing cancer of the cervix in relation to the -308 TNF-alpha gene polymorphism. These OR's were adjusted for the following confounding factors; ethnic group, 5 year age group, years of education, age at first sexual intercourse, number of sexual partners, urban/rural living, number of Pap smears, injectable/oral contraceptive use, smoking, and parity.
###end p 27
###begin title 28
Results
###end title 28
###begin p 29
To evaluate the accuracy of the assigned TNF-alpha genotypes a total of twenty-five samples were randomly chosen and the results were confirmed by repeating the ARMS-PCR. Notably there were no discrepant results detected when the ARMS-PCR assay was repeated on the samples.
###end p 29
###begin p 30
###xml 183 184 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
The genotype distribution of the polymorphism at position -308 of the TNF-alpha promoter region in the cases and controls among the two South African ethnic groups are shown in Table 1. There were no significant differences in the distribution of TNF-alpha allelic polymorphisms and the risk of developing cervical cancer in the mixed race group, (OR, 2.93; 95% CI, 0.51-16.72) or the black group (OR, 0.87; 95% CI, 0.27-2.76). In addition, when the data was adjusted for potential confounding factors (adjusted for 5 year age group, education, age at first sex, number of sexual partners, number of Pap smears, injectable/oral contraceptive use, smoking, and parity), no significant association was observed (data not shown).
###end p 30
###begin p 31
###xml 259 260 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 674 675 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 830 832 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 844 846 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 858 860 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 874 876 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1197 1199 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
As there were no significant differences in the distribution of the -308 TNF-alpha alleles in the cervical cancer patients among the two South African ethnic populations, the data was combined to compare allele distributions to other population groups (Table 2). Interestingly, the genotype distribution of the -308 TNF-a genotypes for the South African cancer cases were different to those reported in a Korean population group (homozygous GG 71% vs 90%; and heterozygous AG 26% vs 6%). In addition, the distributions of the -308 TNF-alpha alleles in the two South African control groups were combined to compare the genotype distribution to other population groups (Table 3). The genotype distribution for the homozygous GG and AA -308 genotypes for the combined South African data were similar to those reported in Zimbabwean [21], Chinese [25]; Italian [26] and Korean [14] populations. However, the distribution of the heterozygous AG genotype was notably different in the Chinese and Korean compared to the South African control group (8% versus 20 %). In addition, there was an increased frequency of the -308 TNF-alpha A allele and decrease in the G allele in the British Caucasoid group [24] when compared to the South African population group.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 101 106 <span type="species:ncbi:9606">women</span>
###xml 376 379 <span type="species:ncbi:10566">HPV</span>
Although the Pap smear screening has reduced cervical cancer mortality in developed countries, 35000 women die from this disease every year in the United States and Europe [27]. The current treatments for cervical cancer are invasive, costly, limited, uncomfortable, inefficient and recurrence is a common outcome [28]. There are several prophylactic and therapeutic clinical HPV vaccine trials that are in progress [29,30], which may assist in reducing this disease burden worldwide. However, while these strategies are commendable it is important to investigate other host or viral markers that contribute to the different stages of cervical disease and thus may provide an effective tool for the treatment of cervical cancer. It is accepted that persistent HRHPV-induced infection is the hallmark of cervical cancer.
###end p 33
###begin p 34
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 449 451 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 452 454 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 455 457 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1129 1130 1113 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 1130 1132 1114 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 229 234 <span type="species:ncbi:9606">women</span>
###xml 251 254 <span type="species:ncbi:10566">HPV</span>
###xml 1064 1072 <span type="species:ncbi:9606">patients</span>
Indeed, other co-factors such as viral load, lifestyle factors, high parity, smoking, long-term use of contraceptives and other sexually transmitted diseases have also been established as risk cofactors for cervical cancer among women with persistent HPV infections [31]. In addition, several studies have indicated that the polymorphisms in the promoter region of -308 TNF-alpha may be a contributing factor for the development of cervical cancer [18,21,32]. However, the results of these studies have been contradictory. Thus in the present study we sought to identify the possible link between -308 A/G TNF-alpha allele polymorphism and the progression of cervical cancer among two ethnic population groups in South Africa. We found no significant differences between the -308TNF-alpha allele polymorphism and cervical cancer risk among the two South African ethnic population groups. In addition we observed no significant differences in the distribution of the high (AA), medium (AG) or low (GG) genotypes of TNF-alpha among the South African cervical cancer patients and healthy controls (and in the combined race groups) (X2 = 2.26) even when the data were adjusted for potential confounders (data not shown).
###end p 34
###begin p 35
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 202 204 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 899 900 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 901 903 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 904 906 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1001 1003 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1254 1256 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1620 1622 1608 1610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1783 1785 1771 1773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 354 359 <span type="species:ncbi:9606">women</span>
The findings in our study are similar to those reported by Stanczuk et al., [21], who investigated the association of -308TNF-alpha gene polymorphism with cervical cancer among a Zimbabwean population [21]. They found no significant differences in the distribution of the high, medium or low producing alleles in the cervical cancer patients and healthy women. However, their study was based on a small sample size and the authors suggested that a larger cohort should be investigated to challenge this association, as their lack of association using a small sample size may have affected the statistical power of the study. Although our study included a large sample size we were unable to confirm this possibility and found no correlation between -308 TNF-alpha polymorphism and the risk of developing cervical cancer among the South African population. Similar reports were documented by others [9,22,33] and discordant with those previously reported in a population group from the United Kingdom [15]. In their study the authors demonstrated that the polymorphism in -308TNF-alpha gene significantly increased the susceptibility to cervical intraepithelial neoplasia 1 (CIN 1). However, as it is well-documented that most CIN1 regress spontaneously [34] it would have been beneficial if the authors extended the follow up screening to 36 months and thus the positive association demonstrated by the authors should be regarded with caution. In addition, CIN1 includes very mild to mild dysplasia, which is characterized by 20-25% replacement of the epithelium with immature cells and generally requires no treatment [29]. Furthermore, although in the same study the recruited subjects were age matched the authors did not provide the ethnic background for the population studied [15]. Thus, it is difficult to conclusively confirm or refute the possible ethnic disparity that may have contributed to the association differences observed between our study population and theirs.
###end p 35
###begin p 36
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 906 907 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1520 1521 1512 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 851 858 <span type="species:ncbi:9606">patient</span>
Several reports in cervical cancer survival studies have indicated that the higher mortality rate in black populations is explained primarily by the more advanced clinical stage at time of diagnosis [35,36]. It was found that the percentage of early diagnosis among blacks and Hispanics were significantly low for cervical and breast cancer compared to non-Hispanics whites. It was therefore suggested that screening programs should be managed differently for specific ethnic groups as there is a significant disparity in the outcome of disease between ethnic populations. [36]. Indeed, the high incidence of cervical cancer in certain population groups may be due to poor screening programs, a lack of stringent follow-up treatments and lower socioeconomic status in different population groups. In the present study, we compared our cervical cancer patient group with those from other populations (Table 2). Although there was a difference in the distribution of the GG and AG of TNF-alpha between our study and the Korean population, this result should be taken with caution as the sample size for the Korean population was very small. It would therefore be valuable if the samples size was increased to examine these relationships adequately. Nevertheless, 26% vs 6% is significant. Furthermore, we compared the distribution of our control study group to those of other populations to identifying whether the distribution of the TNF-alpha gene at position -308 is different in other healthy population groups (Table 3). The distribution of the AATNF-alpha, GGTNF-alpha and AGTNF-alpha genotypes at position -308 in the present control study group were similar to those observed in a Zimbabwean and Italian population and differed from those found in a Caucasian group. In addition, the distribution of the AGTNF-alpha genotype in the South African population group differed from that found in a Chinese and Korean population. These data highlight the possible variability of cytokine gene frequencies in different population groups and hence influence the disease outcome.
###end p 36
###begin title 37
Conclusion
###end title 37
###begin p 38
###xml 231 234 <span type="species:ncbi:10566">HPV</span>
It is important to identify host or viral genetic markers that may facilitate the risk of developing cervical cancer. In addition, these markers would be useful in providing effective treatments and preventative strategies against HPV-induced infections. However, in this study we found no association between -308 TNF-alpha gene polymorphism and the risk of developing cervical cancer. Furthermore, our data highlight the need for further studies to clarify the association of ethnic variation and cytokine polymorphism as other potential confounding factors may contribute to the risk of developing cancer of the cervix.
###end p 38
###begin title 39
Competing interests
###end title 39
###begin p 40
The author(s) declare that they have no competing interests.
###end p 40
###begin title 41
Authors' contributions
###end title 41
###begin p 42
VAG designed the study, carried out the study and drafted the manuscript. DC performed the statistical analysis for the study. MH participated in the design and coordination of the case control study. A-LW participated in the coordination of the study. All authors read and approved the final manuscript.
###end p 42
###begin title 43
Pre-publication history
###end title 43
###begin p 44
The pre-publication history for this paper can be accessed here:
###end p 44
###begin p 45

###end p 45
###begin title 46
Acknowledgements
###end title 46
###begin p 47
The United States National Cancer Institute supported the cancer case-control study (grant number 1 R01 C473985). We thank Shayne Loubsher for technical assistance. VAG was supported by FHS.
###end p 47
###begin article-title 48
Papillomaviruses causing cancer: evasion from host-cell host in early events in carcinogenesis
###end article-title 48
###begin article-title 49
###xml 23 43 <span type="species:ncbi:10566">human papillomavirus</span>
###xml 114 119 <span type="species:ncbi:9606">women</span>
The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women
###end article-title 49
###begin article-title 50
###xml 18 38 <span type="species:ncbi:10566">human papillomavirus</span>
Immunology of the human papillomavirus in relation to cancer
###end article-title 50
###begin article-title 51
###xml 33 53 <span type="species:ncbi:10566">human papillomavirus</span>
###xml 55 58 <span type="species:ncbi:10566">HPV</span>
###xml 99 102 <span type="species:ncbi:10566">HPV</span>
Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia
###end article-title 51
###begin article-title 52
###xml 88 108 <span type="species:ncbi:10566">human papillomavirus</span>
Cytokine production patterns in cervical intraepithelial neoplasia: An association with human papillomavirus infection
###end article-title 52
###begin article-title 53
###xml 69 74 <span type="species:ncbi:9606">women</span>
Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer
###end article-title 53
###begin article-title 54
###xml 73 91 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma
###end article-title 54
###begin article-title 55
Effect of IL-6 polymorphism on risk of Alzheimer disease: Genotype-phenotype association study in Japanese cases
###end article-title 55
###begin article-title 56
Host genetic polymorphism analysis in cervical cancer
###end article-title 56
###begin article-title 57
The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription
###end article-title 57
###begin article-title 58
An endotoxin-induced serum factor that causes necrosis of tumors
###end article-title 58
###begin article-title 59
Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosporylation: Correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1
###end article-title 59
###begin article-title 60
Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide
###end article-title 60
###begin article-title 61
The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers
###end article-title 61
###begin article-title 62
###xml 38 41 <span type="species:ncbi:10566">HPV</span>
TNF alpha polymorphism frequencies in HPV-associated cervical dysplasia
###end article-title 62
###begin article-title 63
Association of polymorphism of IL-10 and TNF-alpha genes with gastric cancer in Korea
###end article-title 63
###begin article-title 64
Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity
###end article-title 64
###begin article-title 65
###xml 51 74 <span type="species:ncbi:333760">human papillomavirus 16</span>
TNF-a promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer
###end article-title 65
###begin article-title 66
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia
###end article-title 66
###begin article-title 67
Tumor necrosis factor alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia
###end article-title 67
###begin article-title 68
Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer
###end article-title 68
###begin article-title 69
###xml 119 142 <span type="species:ncbi:333760">human papillomavirus 16</span>
###xml 156 161 <span type="species:ncbi:9606">women</span>
Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden
###end article-title 69
###begin article-title 70
Limited Pap screening associated with reduced risk of cervical cancer in South Africa
###end article-title 70
###begin article-title 71
ARMS-PCR methodologies to determine IL-10, TNK-alpha and TGF-beta-1 gene polymorphism
###end article-title 71
###begin article-title 72
Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese population
###end article-title 72
###begin article-title 73
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence
###end article-title 73
###begin article-title 74
GLOBOCAN 2002: cancer incidence, motality and prevalence worldwide
###end article-title 74
###begin article-title 75
Management of cervical cancer neoplasia
###end article-title 75
###begin article-title 76
###xml 19 22 <span type="species:ncbi:10566">HPV</span>
###xml 68 71 <span type="species:ncbi:10566">HPV</span>
The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical cancer lesions: Consequences for clinical management
###end article-title 76
###begin article-title 77
###xml 15 20 <span type="species:ncbi:9606">Human</span>
Strategies for Human Papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes
###end article-title 77
###begin article-title 78
###xml 72 92 <span type="species:ncbi:10566">human papillomavirus</span>
Chapter 18: Statistical Issues in the design and analysis of studies of human papillomavirus and cervical neoplasia
###end article-title 78
###begin article-title 79
Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions
###end article-title 79
###begin article-title 80
Papillomavirus vaccines in clinical trials
###end article-title 80
###begin article-title 81
TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk
###end article-title 81
###begin article-title 82
Race, stage of disease, and survival with cervical cancer
###end article-title 82
###begin article-title 83
Differences in stage at presentation of breast and gynecological cancers among whites, blacks, and Hispanics
###end article-title 83
###begin title 84
Figures and Tables
###end title 84
###begin p 85
Odds Ratios and 95% confidence intervals (CI) for the development of cervical cancer in relation to -308 TNF-alpha alleles among the cervical cancer cases and controls in the two South African ethnic population groups.
###end p 85
###begin p 86
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
#All (1) = Mixed race (2) and Black (3) population groups combined
###end p 86
###begin p 87
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
OR1 = crude odds ratio adjusted for ethnic group in the combined ethnic group analysis
###end p 87
###begin p 88
###xml 48 53 <span type="species:ncbi:9606">women</span>
Distribution (%) of -308 TNF-alpha genotypes in women with cervical cancer among different population groups.
###end p 88
###begin p 89
*Combined Black and mixed race cancer case groups in this study (There were no differences in the distribution of the -308 TNF-alpha alleles between the two South African ethnic populations, thus the data was combined to compare genotype distributions to other population groups).
###end p 89
###begin p 90
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 25 31 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 36 48 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#167;</sup>
Data reported by; +[14]; dagger[9]; section sign[21].
###end p 90
###begin p 91
Distribution (%) of -308 TNF-alpha genotypes in the combined South African control population groups and other populations.
###end p 91
###begin p 92
*Combined Black and mixed race control groups in this study (There were no differences in the distribution of the -308 TNF-alpha alleles between the two South African ethnic populations, thus the data was combined to compare genotype distributions to other population groups).
###end p 92
###begin p 93
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 38 44 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 50 62 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#167;</sup>
Data reported by Ë†[25]; #[26]; +[14]; dagger[24]; section sign[21].
###end p 93

